Construction of AstraZeneca’s new global and R&D headquarters in Cambridge should have been completed last autumn – but builders are struggling to meet a revised deadline of May 2019.

The Cambridge Biomedical Campus – already the largest centre of medical research and health science in Europe – could double ...

AstraZeneca has revealed plans to ... News of the investment comes shortly after AZ completed its new headquarters across the Atlantic in Cambridge in the UK, which was built at a cost of around ...

The duality is a hallmark of Greater Boston’s lab market these days. Bright spots surely remain, such as big new lab ...

Multinational pharmaceutical company AstraZeneca said on Monday that Shanghai will be ... Following the four strategic centers in the UK's Cambridge, Boston and Gaithersburg in the United States, and ...

After exiting its California headquarters, Kronos Bio was based out of 301 Binney Street in Cambridge. Now that space is also ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

Earlier this year, AstraZeneca took Imfinzi to new heights in muscle-invasive bladder cancer (MIBC) with an FDA nod that made it the first immunotherapy cleared to treat patients both before and ...

AstraZeneca recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting significant advancements in treatment for high-risk non-muscle-invasive bladder cancer.

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing ...

May 8 (Reuters) - A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the Medicare health insurance plan the power to negotiate ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...